ImmunityBio Statistics
Total Valuation
ImmunityBio has a market cap or net worth of $4.27 billion. The enterprise value is $5.00 billion.
Market Cap | 4.27B |
Enterprise Value | 5.00B |
Important Dates
The next estimated earnings date is Tuesday, August 6, 2024, after market close.
Earnings Date | Aug 6, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
ImmunityBio has 691.57 million shares outstanding. The number of shares has increased by 57.06% in one year.
Shares Outstanding | 691.57M |
Shares Change (YoY) | +57.06% |
Shares Change (QoQ) | +32.28% |
Owned by Insiders (%) | 77.59% |
Owned by Institutions (%) | 9.83% |
Float | 160.49M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 14,151.95 |
Forward PS | 59.59 |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 16,550.26 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.64
Current Ratio | 3.64 |
Quick Ratio | 3.21 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -3.39 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -147.60% |
Return on Capital (ROIC) | -170.57% |
Revenue Per Employee | $481 |
Profits Per Employee | -$956,946 |
Employee Count | 628 |
Asset Turnover | 0.00 |
Inventory Turnover | n/a |
Taxes
Income Tax | -40,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +125.55% in the last 52 weeks. The beta is -0.31, so ImmunityBio's price volatility has been lower than the market average.
Beta (5Y) | -0.31 |
52-Week Price Change | +125.55% |
50-Day Moving Average | 6.90 |
200-Day Moving Average | 4.60 |
Relative Strength Index (RSI) | 44.50 |
Average Volume (20 Days) | 4,007,734 |
Short Selling Information
The latest short interest is 53.44 million, so 7.73% of the outstanding shares have been sold short.
Short Interest | 53.44M |
Short Previous Month | 53.47M |
Short % of Shares Out | 7.73% |
Short % of Float | 33.30% |
Short Ratio (days to cover) | 13.67 |
Income Statement
In the last 12 months, ImmunityBio had revenue of $302,000 and -$600.96 million in losses. Loss per share was -$1.09.
Revenue | 302,000 |
Gross Profit | 302,000 |
Operating Income | -345.87M |
Pretax Income | -601.00M |
Net Income | -600.96M |
EBITDA | -439.89M |
EBIT | -464.13M |
Loss Per Share | -$1.09 |
Balance Sheet
The company has $170.50 million in cash and $894.78 million in debt, giving a net cash position of -$724.29 million or -$1.05 per share.
Cash & Cash Equivalents | 170.50M |
Total Debt | 894.78M |
Net Cash | -724.29M |
Net Cash Per Share | -$1.05 |
Equity (Book Value) | -692.01M |
Book Value Per Share | -1.00 |
Working Capital | 141.96M |
Cash Flow
In the last 12 months, operating cash flow was -$389.43 million and capital expenditures -$23.42 million, giving a free cash flow of -$412.85 million.
Operating Cash Flow | -389.43M |
Capital Expenditures | -23.42M |
Free Cash Flow | -412.85M |
FCF Per Share | -$0.61 |
Margins
Gross margin is 100.00%, with operating and profit margins of -114,525.17% and -198,994.04%.
Gross Margin | 100.00% |
Operating Margin | -114,525.17% |
Pretax Margin | -199,007.28% |
Profit Margin | -198,994.04% |
EBITDA Margin | -145,657.62% |
EBIT Margin | -153,686.42% |
FCF Margin | -136,703.97% |
Dividends & Yields
ImmunityBio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -57.06% |
Shareholder Yield | -57.06% |
Earnings Yield | -14.06% |
FCF Yield | -9.66% |
Analyst Forecast
The average price target for ImmunityBio is $6.00, which is -2.91% lower than the current price. The consensus rating is "Hold".
Price Target | $6.00 |
Price Target Difference | -2.91% |
Analyst Consensus | Hold |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
ImmunityBio has an Altman Z-Score of -11.86 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -11.86 |
Piotroski F-Score | 2 |